Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

Antonio Bianchi; F Valentini; R Iuorio; M Poggi; R Baldelli; M Passeri; Antonella Giampietro; Linda Tartaglione; Sabrina Chiloiro; M Appetecchia; P Gargiulo; A Fabbri; V Toscano; Alfredo Pontecorvi; Laura De Marinis

doi:10.1186/1756-9966-32-40

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

Antonio Bianchi^*
, F Valentini
, R Iuorio
, M Poggi
, R Baldelli
, M Passeri
, Antonella Giampietro
, Linda Tartaglione
, Sabrina Chiloiro
, M Appetecchia
, P Gargiulo
, A Fabbri
, V Toscano
, Alfredo Pontecorvi
, Laura De Marinis

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

30 Citazioni (Scopus)

Abstract

Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).

Lingua originale	Inglese
pagine (da-a)	40-40
Numero di pagine	1
Rivista	Journal of Experimental and Clinical Cancer Research
Volume	32
Numero di pubblicazione	Giugno
DOI	https://doi.org/10.1186/1756-9966-32-40
Stato di pubblicazione	Pubblicato - 2013

All Science Journal Classification (ASJC) codes

Oncologia
Ricerca sul Cancro

Keywords

Acromegaly
Adolescent
Adult
Aged
Antineoplastic Agents
Female
Growth Hormone-Secreting Pituitary Adenoma
Hormonal
Human Growth Hormone
Humans
Male
Middle Aged
Retrospective Studies
Somatostatin
Treatment Outcome
Young Adult

Accesso al documento

10.1186/1756-9966-32-40

Altri file e collegamenti

Fingerprint

Entra nei temi di ricerca di 'Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes'. Insieme formano una fingerprint unica.

Cita questo

Bianchi, A., Valentini, F., Iuorio, R., Poggi, M., Baldelli, R., Passeri, M., Giampietro, A., Tartaglione, L., Chiloiro, S., Appetecchia, M., Gargiulo, P., Fabbri, A., Toscano, V., Pontecorvi, A., & De Marinis, L. (2013). Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. Journal of Experimental and Clinical Cancer Research, 32(Giugno), 40-40. https://doi.org/10.1186/1756-9966-32-40

Bianchi, Antonio ; Valentini, F ; Iuorio, R et al. / Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. In: Journal of Experimental and Clinical Cancer Research. 2013 ; Vol. 32, N. Giugno. pagg. 40-40.

@article{699ba0ff2f0e45368d0161534b6329b5,

title = "Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes",

abstract = "Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).",

keywords = "Acromegaly, Adolescent, Adult, Aged, Antineoplastic Agents, Female, Growth Hormone-Secreting Pituitary Adenoma, Hormonal, Human Growth Hormone, Humans, Male, Middle Aged, Retrospective Studies, Somatostatin, Treatment Outcome, Young Adult, Acromegaly, Adolescent, Adult, Aged, Antineoplastic Agents, Female, Growth Hormone-Secreting Pituitary Adenoma, Hormonal, Human Growth Hormone, Humans, Male, Middle Aged, Retrospective Studies, Somatostatin, Treatment Outcome, Young Adult",

author = "Antonio Bianchi and F Valentini and R Iuorio and M Poggi and R Baldelli and M Passeri and Antonella Giampietro and Linda Tartaglione and Sabrina Chiloiro and M Appetecchia and P Gargiulo and A Fabbri and V Toscano and Alfredo Pontecorvi and \{De Marinis\}, Laura",

year = "2013",

doi = "10.1186/1756-9966-32-40",

language = "English",

volume = "32",

pages = "40--40",

journal = "Journal of Experimental and Clinical Cancer Research",

issn = "0392-9078",

publisher = "BioMed Central",

number = "Giugno",

}

Bianchi, A, Valentini, F, Iuorio, R, Poggi, M, Baldelli, R, Passeri, M, Giampietro, A, Tartaglione, L, Chiloiro, S, Appetecchia, M, Gargiulo, P, Fabbri, A, Toscano, V, Pontecorvi, A & De Marinis, L 2013, 'Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes', Journal of Experimental and Clinical Cancer Research, vol. 32, n. Giugno, pagg. 40-40. https://doi.org/10.1186/1756-9966-32-40

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. / Bianchi, Antonio; Valentini, F; Iuorio, R et al.
In: Journal of Experimental and Clinical Cancer Research, Vol. 32, N. Giugno, 2013, pag. 40-40.

Risultato della ricerca: Contributo in rivista › Articolo

TY - JOUR

T1 - Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

AU - Bianchi, Antonio

AU - Valentini, F

AU - Iuorio, R

AU - Poggi, M

AU - Baldelli, R

AU - Passeri, M

AU - Giampietro, Antonella

AU - Tartaglione, Linda

AU - Chiloiro, Sabrina

AU - Appetecchia, M

AU - Gargiulo, P

AU - Fabbri, A

AU - Toscano, V

AU - Pontecorvi, Alfredo

AU - De Marinis, Laura

PY - 2013

Y1 - 2013

N2 - Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).

AB - Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).

KW - Acromegaly

KW - Adolescent

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Female

KW - Growth Hormone-Secreting Pituitary Adenoma

KW - Hormonal

KW - Human Growth Hormone

KW - Humans

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Somatostatin

KW - Treatment Outcome

KW - Young Adult

KW - Acromegaly

KW - Adolescent

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Female

KW - Growth Hormone-Secreting Pituitary Adenoma

KW - Hormonal

KW - Human Growth Hormone

KW - Humans

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Somatostatin

KW - Treatment Outcome

KW - Young Adult

UR - https://publicatt.unicatt.it/handle/10807/53985

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84879107985&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879107985&origin=inward

U2 - 10.1186/1756-9966-32-40

DO - 10.1186/1756-9966-32-40

M3 - Article

SN - 0392-9078

VL - 32

SP - 40

EP - 40

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

IS - Giugno

ER -

Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M et al. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. Journal of Experimental and Clinical Cancer Research. 2013;32(Giugno):40-40. doi: 10.1186/1756-9966-32-40